Oct 30 (Reuters) - Amgen (AMGN.O), opens new tab reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and osteoporosis, and said mid-stage trial ...
It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug maker’s clutch of approved therapies under its fold. With Horizon’s thyroid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback